Letters

Ginkgo biloba and acetazolamide for acute mountain sickness: Authors' reply

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7458.172-a (Published 15 July 2004) Cite this as: BMJ 2004;329:172
  1. Jeffrey H Gertsch (jeffgertsch@hotmail.com), resident physician,
  2. Buddha Basnyat (nic@naxal.wlink.com.np), medical director,
  3. E William Johnson (billjohn@hawaii.edu), resident physician,
  4. Peter S Holck (holck@hawaii.edu), associate professor
  1. Department of Internal Medicine, Maricopa Medical Center, 2601 E Roosevelt Avenue number O-D-10, Phoenix, AZ 85008, USA
  2. Himalayan Rescue Association, Nepal International Clinic, GPO Box 3596, Laldurbarmag 47, Kathmandu, Nepal
  3. Department of Surgery, University of Washington, Seattle, WA 98195-6410, USA
  4. Department of Public Health Sciences and Epidemiology, University of Hawaii, Honolulu, HI, USA

    EDITOR—The recruitment of Western trekkers in the prevention of high altitude illness trial (PHAIT) study was based on logistics and practicality. Sherpas and other Nepalis residing in or adjacent to the Everest region and above 2000 m are highly resistant to the effects of altitude and would thus be poor research participants. Although many Nepalis working in the Everest region reside at altitudes below 1500 m (potentially eligible research candidates), a fair proportion live in …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe